Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance ...

Danish studies have found a potential link between the diabetes drug Ozempic and a rare eye condition called non-arteritic ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

By Anna Ringstrom and Maggie Fick STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ...

Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to ...

Pharmaceutical companies have an untapped potential to transform global health, but they cannot act alone. Governments, NGOs, ...

Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...